133 related articles for article (PubMed ID: 35094888)
1. Spontaneous remission in juvenile myasthenia gravis: A cohort of 13 cases and review of the literature.
Arroyo HA; Torres AR
Neuromuscul Disord; 2022 Mar; 32(3):213-219. PubMed ID: 35094888
[TBL] [Abstract][Full Text] [Related]
2. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
4. Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis.
Yan C; Li W; Song J; Feng X; Xi J; Lu J; Zhou S; Zhao C
Pediatr Neurol; 2019 Sep; 98():74-79. PubMed ID: 31307830
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and evolution of juvenile myasthenia gravis in a French cohort.
Barraud C; Desguerre I; Barnerias C; Gitiaux C; Boulay C; Chabrol B
Muscle Nerve; 2018 Apr; 57(4):603-609. PubMed ID: 28877546
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
[TBL] [Abstract][Full Text] [Related]
7. Outcome of children with acetylcholine receptor (AChR) antibody positive juvenile myasthenia gravis following thymectomy.
Heng HS; Lim M; Absoud M; Austin C; Clarke D; Wraige E; Reid C; Robb SA; Jungbluth H
Neuromuscul Disord; 2014 Jan; 24(1):25-30. PubMed ID: 24239058
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis in childhood.
Anlar B; Ozdirim E; Renda Y; Yalaz K; Aysun S; Topçu M; Topaloğlu H
Acta Paediatr; 1996 Jul; 85(7):838-42. PubMed ID: 8819551
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
10. Acetylcholine receptor antibodies in juvenile myasthenia gravis.
Andrews PI; Massey JM; Sanders DB
Neurology; 1993 May; 43(5):977-82. PubMed ID: 8492956
[TBL] [Abstract][Full Text] [Related]
11. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
12. Management of Juvenile Myasthenia Gravis.
O'Connell K; Ramdas S; Palace J
Front Neurol; 2020; 11():743. PubMed ID: 32793107
[TBL] [Abstract][Full Text] [Related]
13. Complete stable remission and autoantibody specificity in myasthenia gravis.
Baggi F; Andreetta F; Maggi L; Confalonieri P; Morandi L; Salerno F; Bernasconi P; Montomoli C; Barberis M; Mantegazza R; Antozzi C
Neurology; 2013 Jan; 80(2):188-95. PubMed ID: 23255823
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in juvenile myasthenia gravis-an international cohort study and literature review.
Ramdas S; Della Marina A; Ryan MM; McWilliam K; Klein A; Jacquier D; Alabaf S; Childs AM; Parasuraman D; Beeson D; Palace J; Jungbluth H
Eur J Paediatr Neurol; 2022 Sep; 40():5-10. PubMed ID: 35835035
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.
Huang X; Li Y; Feng H; Chen P; Liu W
Front Neurol; 2018; 9():77. PubMed ID: 29535672
[TBL] [Abstract][Full Text] [Related]
17. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
18. Paediatric myasthenia gravis: Prognostic factors for drug free remission.
Vecchio D; Ramdas S; Munot P; Pitt M; Beeson D; Knight R; Rodríguez Cruz P; Vincent A; Jayawant S; DeVile C; Buckley C; Hilton-Jones D; Robb S; Palace J
Neuromuscul Disord; 2020 Feb; 30(2):120-127. PubMed ID: 32001147
[TBL] [Abstract][Full Text] [Related]
19. HLA antigens and acetylcholine receptor antibody in the subclassification of myasthenia gravis in Hong Kong Chinese.
Hawkins BR; Ip MS; Lam KS; Ma JT; Wy CL; Yeung RT; Dawkins RL
J Neurol Neurosurg Psychiatry; 1986 Mar; 49(3):316-9. PubMed ID: 3958744
[TBL] [Abstract][Full Text] [Related]
20. Acquired myasthenia gravis in childhood.
Evoli A
Curr Opin Neurol; 2010 Oct; 23(5):536-40. PubMed ID: 20581680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
